Miconazole mucoadhesive tablet for oropharyngeal candidiasis

Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability

Oropharyngeal candidiasis is a very common localized infection of the mucus membranes of the oropharynx that is most commonly caused by the patient's own commensal Candida albicans. It is the most common opportunistic infection affecting patients with the human immunodeficiency virus (HIV) and is also quite common in patients with hematological malignancies. Effective treatment options are of h...

Miconazole mucoadhesive tablets: a novel delivery system.

Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effecti...

preparation and pharmaceutical evaluation of miconazole nitrate mucoadhesive film for vaginal candidiasis treatment

Butoconazole and miconazole in treating vaginal candidiasis.

In a single blind trial, a three day course of butoconazole nitrate cream was compared with a seven day course of miconazole nitrate cream, both applied intravaginally, in treating vaginal candidiasis. They were equally effective. The cure rate for patients treated with butoconazole was 82.8% at the first follow up (a mean of 18.4 days from the beginning of the treatment) and 76.7% at second fo...

Neonatal systemic candidiasis treated with miconazole.